Corvus Pharmaceuticals, Inc. (CRVS) Short Interest Update

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) was the recipient of a large increase in short interest in October. As of October 13th, there was short interest totalling 1,293,252 shares, an increase of 39.6% from the September 29th total of 926,344 shares. Currently, 9.5% of the shares of the stock are sold short. Based on an average daily volume of 75,031 shares, the days-to-cover ratio is presently 17.2 days.

Large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. raised its position in Corvus Pharmaceuticals by 29.3% during the second quarter. Russell Investments Group Ltd. now owns 9,286 shares of the company’s stock valued at $112,000 after buying an additional 2,105 shares during the period. New York State Common Retirement Fund raised its position in Corvus Pharmaceuticals by 2,269.1% during the second quarter. New York State Common Retirement Fund now owns 9,500 shares of the company’s stock valued at $115,000 after buying an additional 9,099 shares during the period. TIAA CREF Investment Management LLC raised its position in Corvus Pharmaceuticals by 43.3% during the first quarter. TIAA CREF Investment Management LLC now owns 7,181 shares of the company’s stock valued at $149,000 after buying an additional 2,170 shares during the period. Alliancebernstein L.P. acquired a new position in Corvus Pharmaceuticals during the second quarter valued at $175,000. Finally, California State Teachers Retirement System raised its position in Corvus Pharmaceuticals by 121.2% during the second quarter. California State Teachers Retirement System now owns 14,967 shares of the company’s stock valued at $181,000 after buying an additional 8,200 shares during the period. 83.63% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts recently commented on CRVS shares. Zacks Investment Research upgraded Corvus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Monday, August 28th. Credit Suisse Group upgraded Corvus Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $14.00 price objective for the company in a research report on Wednesday, August 23rd. Wedbush reiterated an “outperform” rating and set a $26.00 price objective on shares of Corvus Pharmaceuticals in a research report on Tuesday, August 8th. Finally, Cowen and Company reiterated an “outperform” rating on shares of Corvus Pharmaceuticals in a research report on Tuesday, July 4th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Corvus Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $20.75.

Shares of Corvus Pharmaceuticals (CRVS) opened at 14.53 on Friday. Corvus Pharmaceuticals has a 52 week low of $13.01 and a 52 week high of $17.64. The firm has a 50-day moving average price of $16.10 and a 200-day moving average price of $16.10. The firm’s market capitalization is $304.17 million.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings results on Thursday, August 3rd. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.03. On average, equities analysts expect that Corvus Pharmaceuticals will post ($3.18) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/28/corvus-pharmaceuticals-inc-crvs-short-interest-update.html.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.

Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply